一般人群中基因变异类型与位置与乳腺癌风险的关联
在CARRIERS联盟32 247例乳腺癌女性与32 544例年龄匹配无乳腺癌女性的年龄校正病例对照分析中,BRCA2外显子11蛋白截短变异(PTV)携带者的乳腺癌风险低于外显子1-10及13-27 PTV携带者,且ER阴性乳腺癌比例更高、诊断年龄更早;其他易感基因PTV未见基因区域间风险差异。
要点
- BRCA2外显子11 PTV携带者乳腺癌风险低于外显子1-10 PTV(OR=13.5)及外显子13-27 PTV(OR=9.0)携带者。
- BRCA2外显子13-27 PTV携带者ER阴性乳腺癌风险低于外显子11 PTV携带者(OR=0.5,95%CI 0.2-0.9,P=0.035)。
- ATM、BRCA1、CHEK2、PALB2的PTV未见基因区域间乳腺癌风险差异。
核心结论
- 基于人群与临床高危队列证实,BRCA2外显子11的PTV与较低的乳腺癌风险、较晚的诊断年龄及较高的ER阴性乳腺癌风险相关。
研究设计与样本
- CARRIERS联盟年龄校正病例对照关联分析,纳入32 247例乳腺癌女性与32 544例年龄匹配无乳腺癌女性。
主要发现
- 与BRCA2外显子11 PTV携带者相比,外显子1-10 PTV携带者乳腺癌风险OR=13.5(95%CI 6.0-38.7,P<0.001),外显子13-27 PTV携带者OR=9.0(95%CI 4.9-18.5,P<0.001)。
- 与BRCA2外显子11 PTV携带者相比,外显子13-27 PTV携带者ER阴性乳腺癌OR=0.5(95%CI 0.2-0.9,P=0.035),外显子1-10 PTV携带者OR=0.5(95%CI 0.1-1.0,P=0.065)。
- 与BRCA2外显子11 PTV携带者相比,外显子13-27 PTV携带者乳腺癌诊断年龄早5.5年(P<0.001),外显子1-10 PTV携带者早2.4年(P=0.169)。
- 上述与ER阴性乳腺癌及诊断年龄的关联在Ambry Genetics高危临床队列及基于人群的UK Biobank队列中得到重复验证。
- 其他易感基因的PTV未见基因区域间乳腺癌风险差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk. It is unknown, however, whether this risk differs by PV type or location in carriers ascertained from the general population. PATIENTS AND METHODS: To evaluate breast cancer risks associated with PV type and location in ATM, BRCA1, BRCA2, CHEK2, and PALB2, we carried out age-adjusted case-control association analysis in 32 247 women with and 32 544 age-matched women without breast cancer from the CARRIERS Consortium. PVs were grouped by type and location within genes and assessed for risks of breast cancer [odds ratios (OR), 95% confidence intervals (CI), and P values] using logistic regression. RESULTS: Compared with women carrying BRCA2 exon 11 protein truncating variants (PTVs) in the CARRIERS population-based study, women with BRCA2 ex1-10 PTVs (OR = 13.5, 95% CI 6.0-38.7, P < 0.001) and ex13-27 PTVs (OR = 9.0, 95% CI 4.9-18.5, P < 0.001) had higher breast cancer risks, lower rates of estrogen receptor (ER)-negative breast cancer (ex13-27 OR = 0.5, 95% CI 0.2-0.9, P = 0.035; ex1-10 OR = 0.5, 95% CI 0.1-1.0, P = 0.065), and earlier age at breast cancer diagnosis (ex13-27 5.5 years, P < 0.001; ex1-10 2.4 years, P = 0.169). These associations with ER-negative breast cancer and age were replicated in a high-risk clinical cohort from Ambry Genetics and the population-based UK Biobank cohort. No differences in risk by gene region were observed for PTVs in other predisposition genes. CONCLUSIONS: Population-based and clinical high-risk cohorts establish that PTVs in exon 11 of BRCA2 are associated with reduced breast cancer risk, later age at diagnosis, and greater risk of ER-negative disease. These differential risks may improve individualized risk prediction and clinical management for women carrying BRCA2 PTVs.
引用
- Akamandisa MP, Boddicker NJ, Yadav S, et al. Association of gene variant type and location with breast cancer risk in the general population. Ann Oncol. 2025. PMID: 40288678. doi:10.1016/j.annonc.2025.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。